IL136867A0 - Triazine compounds for treatment of cns disorders - Google Patents
Triazine compounds for treatment of cns disordersInfo
- Publication number
- IL136867A0 IL136867A0 IL13686798A IL13686798A IL136867A0 IL 136867 A0 IL136867 A0 IL 136867A0 IL 13686798 A IL13686798 A IL 13686798A IL 13686798 A IL13686798 A IL 13686798A IL 136867 A0 IL136867 A0 IL 136867A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- cns disorders
- triazine compounds
- triazine
- cns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9726987.2A GB9726987D0 (en) | 1997-12-22 | 1997-12-22 | Compounds |
| PCT/EP1998/008273 WO1999032462A1 (en) | 1997-12-22 | 1998-12-18 | Triazine compounds for treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL136867A0 true IL136867A0 (en) | 2001-06-14 |
Family
ID=10823992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13686798A IL136867A0 (en) | 1997-12-22 | 1998-12-18 | Triazine compounds for treatment of cns disorders |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US6265405B1 (en) |
| EP (1) | EP1042304A1 (en) |
| JP (1) | JP2001526275A (en) |
| KR (1) | KR20010024800A (en) |
| CN (1) | CN1284951A (en) |
| AP (1) | AP2000001846A0 (en) |
| AR (1) | AR014146A1 (en) |
| AU (1) | AU753874B2 (en) |
| BR (1) | BR9814495A (en) |
| CA (1) | CA2315620A1 (en) |
| CO (1) | CO5011066A1 (en) |
| EA (1) | EA200000561A1 (en) |
| EE (1) | EE200000391A (en) |
| GB (1) | GB9726987D0 (en) |
| GT (1) | GT199800203A (en) |
| HN (1) | HN1998000193A (en) |
| HR (1) | HRP20000419A2 (en) |
| HU (1) | HUP0100611A3 (en) |
| ID (1) | ID25449A (en) |
| IL (1) | IL136867A0 (en) |
| IS (1) | IS5542A (en) |
| JO (1) | JO2065B1 (en) |
| MA (1) | MA26587A1 (en) |
| NO (1) | NO20003211L (en) |
| NZ (1) | NZ505254A (en) |
| PA (1) | PA8465101A1 (en) |
| PE (1) | PE20000063A1 (en) |
| PL (1) | PL341392A1 (en) |
| SK (1) | SK9592000A3 (en) |
| SV (1) | SV1998000151A (en) |
| TR (1) | TR200001970T2 (en) |
| WO (1) | WO1999032462A1 (en) |
| YU (1) | YU39600A (en) |
| ZA (1) | ZA9811725B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0002666D0 (en) | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
| EP1458386B1 (en) * | 2001-12-27 | 2007-04-18 | Ortho-McNeil Pharmaceutical, Inc. | Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| PL213565B1 (en) * | 2002-07-29 | 2013-03-29 | Glaxo Group Ltd | Sustained release formulations comprising lamotrigine |
| CA2514574A1 (en) * | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Use of sodium channel modulators for treating gastrointestinal tract disorders |
| AR044503A1 (en) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | TRIAZOLS REPLACED WITH BIARILO AS BLOCKERS OF THE SODIUM CHANNEL |
| DE10332472A1 (en) * | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of tinnitus |
| ES2339021T3 (en) * | 2003-08-25 | 2010-05-14 | Newron Pharmaceuticals S.P.A. | USEFUL ALFA-AMINOAMIDE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS. |
| US20060115865A1 (en) * | 2004-10-25 | 2006-06-01 | Anlong Ouyang | Lamotrigine analogs |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| EP3524605B1 (en) * | 2018-02-13 | 2019-11-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | New efficient process for the preparation of sitagliptin |
| CN114796146B (en) * | 2022-04-28 | 2023-03-28 | 上海奥科达医药科技股份有限公司 | Slow-release preparation of lamotrigine and preparation method thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3637688A (en) | 1970-01-09 | 1972-01-25 | American Home Prod | 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines |
| EP0021120B1 (en) | 1979-06-01 | 1983-04-06 | The Wellcome Foundation Limited | 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them |
| DK153787C (en) * | 1979-06-01 | 1989-01-16 | Wellcome Found | METHOD OF ANALOGUE FOR THE PREPARATION OF SUBSTITUTED 3,5-DIAMINO-6-PHENYL-1,2,4-TRIAZINES AND ALFA-CYANOBENZYLIDEEN-AMINOGUANIDE COMPOUNDS FOR USE AS INTERMEDIATES |
| EP0086502B1 (en) | 1979-08-16 | 1987-03-25 | The Wellcome Foundation Limited | Substituted aromatic triazines |
| GB8328757D0 (en) | 1983-10-27 | 1983-11-30 | Wellcome Found | Chemical compounds |
| GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9012312D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9203483D0 (en) | 1992-02-19 | 1992-04-08 | Wellcome Found | Anti-inflammatory compounds |
| SK279730B6 (en) | 1992-06-12 | 1999-02-11 | The Wellcome Foundation Ltd | Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine and its pharmaceutically and veterinarily acceptable salts |
| WO1994014780A1 (en) | 1992-12-18 | 1994-07-07 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
| US5866597A (en) | 1993-03-19 | 1999-02-02 | Glaxo Wellcome Inc. | Use of triazine compounds for the treatment of memory and learning disorders |
| GB9305692D0 (en) | 1993-03-19 | 1993-05-05 | Wellcome Found | Therapeutic triazine compounds and use |
| GB9426448D0 (en) | 1994-12-30 | 1995-03-01 | Wellcome Found | Process |
| FR2741879A1 (en) | 1995-12-05 | 1997-06-06 | Esteve Labor Dr | FLUOROPHENYL-TRIAZINE AND PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS |
-
1997
- 1997-12-22 GB GBGB9726987.2A patent/GB9726987D0/en not_active Ceased
-
1998
- 1998-12-18 IL IL13686798A patent/IL136867A0/en unknown
- 1998-12-18 NZ NZ505254A patent/NZ505254A/en unknown
- 1998-12-18 CO CO98075403A patent/CO5011066A1/en unknown
- 1998-12-18 US US09/582,058 patent/US6265405B1/en not_active Expired - Fee Related
- 1998-12-18 HU HU0100611A patent/HUP0100611A3/en unknown
- 1998-12-18 SV SV1998000151A patent/SV1998000151A/en unknown
- 1998-12-18 ID IDW20001416A patent/ID25449A/en unknown
- 1998-12-18 EA EA200000561A patent/EA200000561A1/en unknown
- 1998-12-18 PL PL98341392A patent/PL341392A1/en unknown
- 1998-12-18 YU YU39600A patent/YU39600A/en unknown
- 1998-12-18 SK SK959-2000A patent/SK9592000A3/en unknown
- 1998-12-18 EP EP98966635A patent/EP1042304A1/en not_active Withdrawn
- 1998-12-18 AP APAP/P/2000/001846A patent/AP2000001846A0/en unknown
- 1998-12-18 AR ARP980106526A patent/AR014146A1/en not_active Application Discontinuation
- 1998-12-18 JP JP2000525399A patent/JP2001526275A/en active Pending
- 1998-12-18 KR KR1020007006947A patent/KR20010024800A/en not_active Application Discontinuation
- 1998-12-18 CA CA002315620A patent/CA2315620A1/en not_active Abandoned
- 1998-12-18 EE EEP200000391A patent/EE200000391A/en unknown
- 1998-12-18 BR BR9814495-2A patent/BR9814495A/en not_active IP Right Cessation
- 1998-12-18 AU AU24147/99A patent/AU753874B2/en not_active Ceased
- 1998-12-18 TR TR2000/01970T patent/TR200001970T2/en unknown
- 1998-12-18 WO PCT/EP1998/008273 patent/WO1999032462A1/en not_active Application Discontinuation
- 1998-12-18 CN CN98813745A patent/CN1284951A/en active Pending
- 1998-12-21 PA PA19988465101A patent/PA8465101A1/en unknown
- 1998-12-21 JO JO19982065A patent/JO2065B1/en active
- 1998-12-21 PE PE1998001255A patent/PE20000063A1/en not_active Application Discontinuation
- 1998-12-21 ZA ZA9811725A patent/ZA9811725B/en unknown
- 1998-12-22 MA MA25403A patent/MA26587A1/en unknown
- 1998-12-22 GT GT199800203A patent/GT199800203A/en unknown
-
1999
- 1999-12-21 HN HN1998000193A patent/HN1998000193A/en unknown
-
2000
- 2000-06-20 IS IS5542A patent/IS5542A/en unknown
- 2000-06-21 NO NO20003211A patent/NO20003211L/en unknown
- 2000-06-21 HR HR20000419A patent/HRP20000419A2/en not_active Application Discontinuation
-
2001
- 2001-07-06 US US09/899,198 patent/US6465461B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL116998A0 (en) | Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders | |
| EP0889888A4 (en) | Novel treatment for cns injuries | |
| EP0889887A4 (en) | Novel treatment for cns injuries | |
| EP1274444A4 (en) | Compounds for the treatment of psychiatric or substance abuse disorders | |
| PL336290A1 (en) | Sulphonamides for treating endothelin-involving disorders | |
| IL138129A (en) | Composition for therapy of estrogen-associated disorders | |
| IL134289A0 (en) | Methods for treating neurological deficits | |
| IL141263A0 (en) | Methods for treatment of neurological disorders | |
| EP0991412A4 (en) | Aminoacyl sulfamides for the treatment of hyperproliferative disorders | |
| IL117016A0 (en) | Purification of melamine | |
| IL128505A0 (en) | Process for the preparation of pyrimidine compounds | |
| IL145696A0 (en) | Method for the treatment of neurological or neuropsychiatric disorders | |
| IL136867A0 (en) | Triazine compounds for treatment of cns disorders | |
| GB2318350B (en) | Process for purification of hydrochlorofluoroethanes | |
| HUP0004030A3 (en) | Process for the purification of aspartame derivative | |
| PL332821A1 (en) | Pyrazolydinones for treating potency disorders | |
| SI1468686T1 (en) | S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders | |
| SG82014A1 (en) | The use of aryl-cyclohexylamine derivatives against cns disorders | |
| IL139018A0 (en) | Paroxetine 10-camphorsulfonate for treatment of cns disorders | |
| IL122077A0 (en) | Epi-inositol compositions for the treatment of CNS disorders | |
| AU7521598A (en) | Aralkoxy-morphinan derivatives for treatment of cns disorders | |
| IL131765A0 (en) | Process for the purification of substituted p-nitrodiphenylethers | |
| SI1049672T1 (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
| SI1049670T1 (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
| GB9821610D0 (en) | Treatment of neuropsychiatric disorders |